Pembrolizumab Untreated Lung Cancer Trial Completes Primary Phase

The primary phase of the Phase 3 study (NCT04746924) evaluating pembrolizumab in participants with untreated lung cancer completed on May 30, 2025. This trial compares pembrolizumab to a combination of ociperlimab and tislelizumab in this patient population.

Background

The trial involves pembrolizumab, also known by its brand name Keytruda, as one of the key interventions being evaluated. The study population focuses on adults with PD-L1 high, locally advanced/recurrent or untreated metastatic NSCLC, representing a significant area of unmet medical need in oncology for new therapeutic options.

Trial design

The study, identified as NCT04746924, is a Phase 3 clinical trial with an enrollment of 662 participants. The primary focus of the study is on Non-small Cell Lung Cancer (NSCLC). Specifically, the trial's purpose is to evaluate the efficacy and safety of a combination regimen of ociperlimab + tislelizumab. This combination is being compared against pembrolizumab alone in adults diagnosed with PD-L1 high, locally advanced/recurrent or untreated metastatic NSCLC.

What this means

The primary completion of this Phase 3 study signifies that all necessary data for the trial's primary endpoints have been collected. This is a crucial step in the clinical development process, paving the way for comprehensive data analysis and the eventual disclosure of results. These forthcoming results will be vital for understanding the comparative efficacy and safety profiles of ociperlimab + tislelizumab versus pembrolizumab in the context of untreated lung cancer, potentially informing future treatment guidelines and patient care strategies.

Source

The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a publicly accessible database of clinical studies. The update for study NCT04746924, titled "A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer," was recorded with a primary completion date of May 30, 2025 on clinicaltrials.gov.